Dr. Shui On LEUNG , Chairman of SinoMab, was Invited to Attend IFRA 2023 Showcases the Clinical Trial Results of SM03 (Suciraslimab) and Receives International Recognition

[For Immediate Release] 中國抗體製藥有限公司 SinoMab BioScience Limited (Incorporated in Hong Kong with limited liability) (Stock Code: 3681) Dr. Shui On LEUNG, Chairman of SinoMab, was Invited to Attend IFRA 2023 Showcases the Clinical Trial Results of SM03 (Suciraslimab) and Receives International Recognition (19 September 2023 – Hong Kong), A Hong Kong-based biopharmaceutical Company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”) , is pleased to announce that Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company, has been honored to be invited to participate in "the 15th International Forum on Rheumatoid Arthritis (IFRA 2023)" and held a thematic discussion of “ Correlation between the clinical outcome and MOA of anti -CD22 antibody for the treatment of autoimmune diseases” on the keynote forum, which fully affirmed the academic contribution and outstanding performance of the Company’s management and research team in the field of rheumatoid arthritis (‘‘RA’’) treatment, and the achievements have been recognized and acknowledged. IFRA 2023, held in Beijing from 15 to 17 September 2023, is an international annual event in the field of RA diseases. The conference brought together renowned experts from the National College of Rheumatology and more than 40 world-class experts in RA diseases, exploring the frontier academic achievements of the global RA field . Dr. Shui On LEUNG , an executive Director, the Chairman and the Chief Executive Officer of the Company, with over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies, was honored to be invited as a guest speaker to give a speech at the keynote forum. This invitation affirms his personal and the Company's contributions and achievements in the field of RA , which have been widely recognized by the academic community. At the forum, Dr. Shui On LEUNG conducted a panel discussion on the theme of “ Correlation between the clinical outcome of anti-CD22 antibody for the treatment of autoimmune diseases ” to share the mechanism of action (“MOA”) of anti-CD22 antibody for the treatment of autoimmune diseases and the research progress of the Company’s flagship product SM03 (Suciraslimab). Our research team discovered that, by conversion of cis-binding CD22 to trans-binding CD22, immunosuppressive molecules such as SHP-1 could be recruited and thus suppressing relevant immune responses. This MOA of SM03 is consistent with the results observed in the Phase II clinical trial, and explains why SM03 can break through the limitations of traditional therapies in terms of efficacy and safety. Recently, SM03’s research in the rheumatoid arthritis field is progressing well. The Phase III clinical trial in China has achieved the primary endpoint and showed that SM03 could effectively suppress disease activity and alleviate symptoms of active RA patients . Detailed results of clinical data and analysis will be published in medical journals. Meanwhile, the National Medical Products Administration of China (the ‘‘NMPA’’) has accepted the biologics license application (‘‘BLA’’) for SM03, in the treatment of RA on 5 September 2023. This significant milestone marks the official commencement of countdown towards achieving commercial profitability. SM03 (Suciraslimab) is our self developed product, and is a global first -in-target anti -CD22 monoclonal antibody for the treatment of rheumatoid arthritis and other autoimmune diseases. It adopts a novel mechanism of action that differentiates itself from the current treatments available in the market. By targeting the unique B-cell receptor CD22, SM03 specifically overcomes the deficiency of drug resistance against mature RA targets observed with long -term use of conventional treatments. As a result, it holds great potential for delivering significant clinical benefits to patients with rheumatoid arthritis. Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company , said, “I am honored to be invited as a speaker to attend IFRA 2023. The panel discussion shared the MOA and clinical performance of SM03 (Suciraslimab), which aroused interest and lively discussions among experts and scholars at the conference, affirming the originality and uniqueness of SM03. B-cells play an important role in autoimmune diseases, and the significant results of the trial of SM03 (Suciraslimab) against RA will be beneficial for the development of other indications related to B -cell disorders in the future. Recently, the domestic RA market has been expanding rapidly, and the demand for treatment has also increased year by year. With the successful commencement of clinical studies and positive clinical data for our flagship product SM03 (Suciraslimab), we expect to obtain the world's first marketed CD22-targeted new drug approval for the treatment of RA, and we are also actively advancing the commerciali sation process. We hope that SM03 (Suciraslimab) will benefit RA patients in China and around the world soon, inject ing new vitality into RA treatment field. RA research is a long and challenging journey. As a biopharmaceutical Company dedicated to the immunological diseases, we will continue to implement independent innovation, be clinical-value-oriented, and work with industry peers to bring more breakthroughs in the treatment of RA and make strong contributions to the global health industry." IFRA 2023 Panel Discussion (Centre: Dr. Shui On LEUNG) – END – About SinoMab BioScience Limited SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. About the 15th International Forum on Rheumatoid Arthritis (IFRA) The 15th International Forum on Rheumatoid Arthritis (IFRA 2023) was held in Beijing from 15 to 17 September2023, an international annual event for the rheumatology and autoimmune sector. Since its establishment in 2009, the conference has successfully hel d 14 sessions, which served as a bridge for communication and exchange between domestic and foreign scholars, and provided a platform for learning and growth for colleagues in the RA industry. It was a wonderful academic feast. The conference gathered leading rheumatologists from the United States, the United Kingdom, Germany, the Netherlands, Austria, Sweden, Japan and other countries and regions, and renowned experts from the National Rheumatology Association acted as the host or guest speakers. More than 40 speakers were world -class rheumatology and immunology experts. The theme of this session is “Focus on Progress, Focus on Clinical and Sharing Practises”, and academic exchanges will be conducted on RA pathogenesis (immunity, inflammation and molecular genetics) and the latest progress of diagnosis and treatment. This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact: Financial PR (HK) Limited Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Willa Xue Email: [email protected] Tel: Fax: (852) 2610 0846 (852) 2610 0842

The release as fetched from its publisher. sinomab.com ↗